CLINICAL TRIALS PROFILE FOR FORTAMET
✉ Email this page to a colleague
All Clinical Trials for FORTAMET
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00087516 ↗ | Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-021) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2004-06-01 | The purpose of this clinical study is to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus. |
| NCT00344851 ↗ | Exenatide and Metformin Therapy in Overweight Women With PCOS | Completed | Amylin Pharmaceuticals, LLC. | Phase 2 | 2006-06-01 | Current research has shown that the use of diabetes management practices aimed at reducing insulin resistance and hyperinsulinemia (such as weight reduction and the administration of oral antidiabetic drugs) in women with PCOS can not only improve glucose and lipid metabolism but can also reverse testosterone abnormalities and restore menstrual cycles. A new medicine called exenatide (Byetta) has been found to reduce body weight, as well as, improve abnormal glucose metabolism in diabetics. This randomized study will compare Exenatide (Byetta) to extended release metformin (Fortamet) to combination therapy (both Byetta and Fortamet) on menstrual cyclicity, hormone profiles and metabolic profiles over a 24-week period in women with PCOS. |
| NCT00344851 ↗ | Exenatide and Metformin Therapy in Overweight Women With PCOS | Completed | Metabolic Center of Louisiana Research Foundation | Phase 2 | 2006-06-01 | Current research has shown that the use of diabetes management practices aimed at reducing insulin resistance and hyperinsulinemia (such as weight reduction and the administration of oral antidiabetic drugs) in women with PCOS can not only improve glucose and lipid metabolism but can also reverse testosterone abnormalities and restore menstrual cycles. A new medicine called exenatide (Byetta) has been found to reduce body weight, as well as, improve abnormal glucose metabolism in diabetics. This randomized study will compare Exenatide (Byetta) to extended release metformin (Fortamet) to combination therapy (both Byetta and Fortamet) on menstrual cyclicity, hormone profiles and metabolic profiles over a 24-week period in women with PCOS. |
| NCT00443755 ↗ | Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance | Completed | National Center for Research Resources (NCRR) | Phase 2 | 2005-08-01 | The objective of this study is to determine whether targeted pharmacological improvement of insulin sensitivity will normalize the associated elevations of thrombotic and inflammatory cardiovascular disease (CVD) biomarkers in individuals with insulin resistance. |
| NCT00443755 ↗ | Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 2 | 2005-08-01 | The objective of this study is to determine whether targeted pharmacological improvement of insulin sensitivity will normalize the associated elevations of thrombotic and inflammatory cardiovascular disease (CVD) biomarkers in individuals with insulin resistance. |
| NCT00443755 ↗ | Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance | Completed | Takeda Pharmaceuticals North America, Inc. | Phase 2 | 2005-08-01 | The objective of this study is to determine whether targeted pharmacological improvement of insulin sensitivity will normalize the associated elevations of thrombotic and inflammatory cardiovascular disease (CVD) biomarkers in individuals with insulin resistance. |
| NCT00443755 ↗ | Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance | Completed | Mayo Clinic | Phase 2 | 2005-08-01 | The objective of this study is to determine whether targeted pharmacological improvement of insulin sensitivity will normalize the associated elevations of thrombotic and inflammatory cardiovascular disease (CVD) biomarkers in individuals with insulin resistance. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for FORTAMET
Condition Name
Clinical Trial Locations for FORTAMET
Trials by Country
Clinical Trial Progress for FORTAMET
Clinical Trial Phase
Clinical Trial Sponsors for FORTAMET
Sponsor Name
